Physician profile

John R Gregory

Surgery · Billings, MT

NPI 1861504847

$3,275.07

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$348.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,822.39 2019-2024
Ethicon INC. $743.71 2021
Kci USA, INC. $146.95 2019-2021
Medtronic, INC. $119.50 2023 Signia
Astrazeneca Pharmaceuticals LP $107.09 2019
Acell, INC. $90.80 2019
Lemaitre Vascular, INC. $86.53 2023-2024 Artegraft Vascular Graft, Restoreflow
Baxter Healthcare $79.22 2021-2023 Floseal
Allergan, INC. $50.55 2019
Olympus America INC. $28.33 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John R Gregory

$3,275.07

in general payments reported 2019-2025

Years
2019-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/701603/john-r-gregory

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.